A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer

NCT01590719 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Placebo
DRUG: Onartuzumab (MetMAb)
DRUG: Oxaliplatin
DRUG: Folinic acid
DRUG: Levofolinic acid
DRUG: 5-Fluorouracil

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]